Newly Released Peer-Reviewed Publication Further Validates RepliCel’s Use of Dermal Sheath Cup Cells to Treat Pattern Baldness
RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSX.V: RP), a clinical stage regenerative medicine company focused on the development of autologous cell therapies, announced today the publication of a paper out of the University of Calgary in conjunction with co-authors from Kyoto University and the University of North Carolina, which further validates the company's ongoing clinical research using dermal sheath cup (DSC) cells to reverse the effects of pattern baldness.
Please sign in or register for FREE
Sign in to RegMedNet
Register to RegMedNet
RegMedNet is a free content and networking hub promoting global connection, knowledge-sharing and collaboration between all members of the regenerative medicine field.